{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T12:49:27Z","timestamp":1780058967186,"version":"3.54.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T00:00:00Z","timestamp":1597536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T00:00:00Z","timestamp":1597536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s40265-020-01381-1","type":"journal-article","created":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T10:02:51Z","timestamp":1597572171000},"page":"1337-1344","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Lenalidomide: A Review in Previously Treated Follicular Lymphoma"],"prefix":"10.1007","volume":"80","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,16]]},"reference":[{"issue":"24","key":"1381_CR1","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1182\/blood.2019001751","volume":"135","author":"C Flowers","year":"2020","unstructured":"Flowers C, Leonard JP, Fowler N. Lenalidomide in follicular lymphoma. Blood. 2020;135(24):2133\u20136.","journal-title":"Blood."},{"issue":"3","key":"1381_CR2","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/ajh.25696","volume":"95","author":"A Freedman","year":"2020","unstructured":"Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2020;95(3):316\u201327.","journal-title":"Am J Hematol."},{"key":"1381_CR3","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.16686.1","author":"P Feugier","year":"2019","unstructured":"Feugier P, Filliatre-Clement L. Recent advances in the first-line treatment of follicular non-Hodgkin lymphoma. F1000Research. 2019. https:\/\/doi.org\/10.12688\/f1000research.16686.1.","journal-title":"F1000Research"},{"key":"1381_CR4","unstructured":"Lymphoma Research Foundation. Follicular lymphoma: relapsed\/refractory. 2018. http:\/\/www.lymphoma.org. Accessed 5 Aug 2020."},{"issue":"Suppl 5","key":"1381_CR5","doi-asserted-by":"publisher","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","volume":"27","author":"M Dreyling","year":"2016","unstructured":"Dreyling M, Ghielmini M, Rule S, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl 5):v83\u201390.","journal-title":"Ann Oncol."},{"key":"1381_CR6","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae): B-cell lymphomas. 2020. http:\/\/www.nccn.org. Accessed 5 Aug 2020."},{"issue":"2","key":"1381_CR7","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/annonc\/mdx768","volume":"29","author":"R Karmali","year":"2018","unstructured":"Karmali R, Kimby E, Ghielmini M, et al. Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas. Ann Oncol. 2018;29(2):332\u201340.","journal-title":"Ann Oncol."},{"key":"1381_CR8","unstructured":"Celgene Corporation. REVLIMID (lenalidomide capsule): US prescribing information. 2019. http:\/\/dailymed.nlm.nih.gov. Accessed 5 Aug 2020."},{"key":"1381_CR9","unstructured":"National Institute for Health and Care Excellence. Treating follicular lymphoma. 2020. http:\/\/www.nice.org.uk. Accessed 5 Aug 2020."},{"key":"1381_CR10","unstructured":"European Medicines Agency. Revlimid (lenalidomide) hard capsules: summary of product characteristics. 2020. http:\/\/www.ema.europa.eu. Accessed 5 Aug 2020."},{"issue":"5","key":"1381_CR11","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40266-015-0269-6","volume":"32","author":"PL McCormack","year":"2015","unstructured":"McCormack PL. Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation. Drugs Aging. 2015;32(5):409\u201318.","journal-title":"Drugs Aging."},{"issue":"5","key":"1381_CR12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.2165\/11206420-000000000-00000","volume":"71","author":"LJ Scott","year":"2011","unstructured":"Scott LJ, Lyseng-Williamson KA. Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs. 2011;71(5):625\u201349.","journal-title":"Drugs."},{"issue":"13","key":"1381_CR13","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s40265-017-0795-0","volume":"77","author":"YY Syed","year":"2017","unstructured":"Syed YY. Lenalidomide: a review in newly diagnosed multiple myeloma as maintenance therapy after ASCT. Drugs. 2017;77(13):1473\u201380.","journal-title":"Drugs."},{"issue":"11","key":"1381_CR14","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s40265-013-0071-x","volume":"73","author":"YY Syed","year":"2013","unstructured":"Syed YY, Scott LJ. Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion. Drugs. 2013;73(11):1183\u201396.","journal-title":"Drugs."},{"issue":"25","key":"1381_CR15","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","volume":"33","author":"JG Gribben","year":"2015","unstructured":"Gribben JG, Fowler N, Morschhauser F. Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol. 2015;33(25):2803\u201311.","journal-title":"J Clin Oncol."},{"issue":"2","key":"1381_CR16","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/bjh.15797","volume":"185","author":"H Chiu","year":"2019","unstructured":"Chiu H, Trisal P, Bjorklund C, et al. Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma. Br J Haematol. 2019;185(2):240\u201353.","journal-title":"Br J Haematol."},{"issue":"14","key":"1381_CR17","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.19.00010","volume":"37","author":"JP Leonard","year":"2019","unstructured":"Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37(14):1188\u201399.","journal-title":"J Clin Oncol."},{"issue":"Suppl. 1","key":"1381_CR18","first-page":"540","volume":"4","author":"MJ Rummel","year":"2020","unstructured":"Rummel MJ, Andorsky DJ, Coleman M, et al. MAGNIFY: phase IIIb interim analysis of induction lenalidomide + rituximab (R2) followed by maintenance in relapsed\/refractory indolent non-Hodgkin lymphoma [abstract no. EP1161]. Hemasphere. 2020;4(Suppl. 1):540.","journal-title":"Hemasphere."},{"issue":"3","key":"1381_CR19","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/bjh.12755","volume":"165","author":"JM Tuscano","year":"2014","unstructured":"Tuscano JM, Dutia M, Chee K, et al. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. Br J Haematol. 2014;165(3):375\u201381.","journal-title":"Br J Haematol."},{"issue":"3","key":"1381_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s12185-019-02802-y","volume":"111","author":"K Izutsu","year":"2019","unstructured":"Izutsu K, Minami Y, Fukuhara N, et al. Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed\/refractory indolent non-Hodgkin lymphoma. Int J Hematol. 2019;111(3):409\u201316.","journal-title":"Int J Hematol."},{"issue":"Suppl 2","key":"1381_CR21","first-page":"S67","volume":"41","author":"A Scheliga","year":"2019","unstructured":"Scheliga A, Fogliatto L, Scheinberg P, et al. Analysis of Brazilian patients (pts) from AUGMENT: a phase III randomized study of lenalidomide plus rituximab vs rituximab plus placebo in pts with relapsed\/refractory (R\/R) indolent non-hodgkin lymphoma (INHL) [abstract no. 179 plus poster 348]. Hematol Transfus Cell Ther. 2019;41(Suppl 2):S67.","journal-title":"Hematol Transfus Cell Ther."},{"key":"1381_CR22","doi-asserted-by":"crossref","unstructured":"Trneny M, Leonard J, Zhang H, et al. Subgroup analyses of elderly patients aged \u2265 70 years in AUGMENT: a phase III randomized study of lenalidomide plus rituximab (R2) vs rituximab plus placebo in patients with relapsed\/refractory indolent non-Hodgkin lymphoma [abstract no. 009 plus oral presentation]. In: Prague Hematological Days. 2019.","DOI":"10.1182\/blood-2019-122461"},{"issue":"Suppl 1","key":"1381_CR23","first-page":"193","volume":"3","author":"JP Leonard","year":"2019","unstructured":"Leonard JP, Trneny M, Izutsu K, et al. Efficacy was improved with lenalidomide\/rituximab (R2) vs rituximab\/placebo in patients with follicular lymphoma irrespective of POD24 status in the phase III AUGMENT study [abstract no. PF483]. HemaSphere. 2019;3(Suppl 1):193\u20134.","journal-title":"HemaSphere."},{"issue":"Suppl 2","key":"1381_CR24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/hon.42_2630","volume":"37","author":"J Gribben","year":"2019","unstructured":"Gribben J, Trneny M, Izutsu K, et al. AUGMENT: relapsed\/refractory indolent NHL patients were more sensitive to next treatment following lenalidomide\/rituximab (R2) than rituximab\/placebo [abstract no 178]. Hematol Oncol. 2019;37(Suppl 2):227\u20139.","journal-title":"Hematol Oncol."},{"issue":"Suppl 2","key":"1381_CR25","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/hon.45_2630","volume":"37","author":"JP Leonard","year":"2019","unstructured":"Leonard JP, Trneny M, Izutsu K, et al. Health-related quality of life (HRQoL) in relapsed\/refractory (R\/R) indolent NHL in the phase 3 AUGMENT trial of rituximab (R) plus lenalidomide (R2) versus R plus placebo [abstract no. 181]. Hematol Oncol. 2019;37(Suppl 2):232\u20134.","journal-title":"Hematol Oncol."},{"key":"1381_CR26","unstructured":"US National Institutes of Health. http:\/\/www.clinicaltrials.gov. Accessed 5 Aug 2020"},{"key":"1381_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.03.009","author":"BD Cheson","year":"2020","unstructured":"Cheson BD, Morschhauser F, Martin P. Management of adverse events from the combination of rituximab and lenalidomide in the treatment of patients with follicular and low-grade non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2020. https:\/\/doi.org\/10.1016\/j.clml.2020.03.009.","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"1381_CR28","unstructured":"National Institute for Health and Care Excellence. Lenalidomide with rituximab for previously treated follicular lymphoma. 2020. http:\/\/www.nice.org.uk. Accessed 5 Aug 2010."},{"issue":"8","key":"1381_CR29","doi-asserted-by":"publisher","first-page":"657","DOI":"10.2165\/11314820-000000000-00000","volume":"27","author":"T Foster","year":"2009","unstructured":"Foster T, Miller JD, Boye ME, et al. Economic burden of follicular non-Hodgkin\u2019s lymphoma. Pharmacoeconomics. 2009;27(8):657\u201379.","journal-title":"Pharmacoeconomics."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01381-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-020-01381-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01381-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T16:57:51Z","timestamp":1659113871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-020-01381-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,16]]},"references-count":29,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["1381"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01381-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,16]]},"assertion":[{"value":"16 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"H. Blair is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}